Pharmacokinetic Study of Alpelisib in Subjects With Hepatic Impairment.

NCT02624557 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

23

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatic Impairment

Interventions

DRUG: Alpelisib

Sponsor

Novartis Pharmaceuticals